2026-04-17T20:13:38Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/136702025-10-24T02:03:33Zcom_2072_378070com_2072_378040com_2072_378071col_2072_378092col_2072_378097

00925njm 22002777a 4500 dc Serna, Angel author Iraola, Josu author Garcia-Herce, Cristina author Falcó Roget, Anna author Navarro Garces, Victor author Jiménez, Moraima author Bosch Schips, Marc author Albasanz Puig, Adaia author Ruiz- Camps, Isabel author Esperalba, Juliana author Cecilia del Carmen, Carpio Segura author Crespo, Marta author IACOBONI, GLORIA author Marin Niebla, Ana author Bosch, Francesc author Abrisqueta, Pau author Antón Pagarolas, Andrés author Andrés Vergés, Cristina author 2025-09-16T12:24:22Z 2025-09-16T12:24:22Z 2025-08-26 SARS-CoV-2 infection; Bispecific antibody; B-cell lymphoproliferative disorders Infecció per SARS-CoV-2; Anticossos biespecífics; Trastorns limfoproliferatius de cèl·lules B Infección por SARS-CoV-2; Anticuerpos biespecíficos; Trastornos linfoproliferativos de células B Despite advances in vaccination and the use of antiviral treatments, patients with hematologic malignancies, including B-cell lymphoproliferative disorders, are particularly vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The recent introduction of bispecific antibodies (BsAbs) in the treatment algorithm of relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL) has raised concerns regarding their impact on COVID-19 outcomes. This study aimed to evaluate the impact of SARS-CoV-2 infection on treatment outcomes in patients receiving BsAbs. We assessed the severity of COVID-19 and SARS-CoV-2 serostatus, with antibody titers measured before, during, and after BsAbs administration. A total of 109 patients with B-NHL treated with BsAbs from March 2020 to January 2023 were included. SARS-CoV-2 infection was observed in 56 patients (51%), with 36% experiencing prolonged viral shedding, causing therapy delays in 78% of patients and permanent discontinuations in 19%. Regarding COVID-19 severity, 36% of patients presented moderate, 20% severe, and 12% critical disease. Seven patients (13%) died owing to COVID-19 pneumonia. Similar to observations with anti-CD20 monoclonal antibodies, BsAbs were associated with negative antispike serostatus for at least 6 months after treatment completion. Importantly, this lack of seroconversion was linked with severe disease and increased mortality. These findings underscore important considerations for the management of patients receiving BsAbs. This work was supported by the Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias (PI22/01204). Immunoglobulines - Ús terapèutic Limfomes - Tractament Sang - Malalties - Tractament COVID-19 (Malaltia) DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Bispecific Other subheadings::Other subheadings::/therapeutic use DISEASES::Neoplasms::Neoplasms by Site::Hematologic Neoplasms DISEASES::Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, B-Cell Other subheadings::Other subheadings::Other subheadings::/drug therapy ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos biespecíficos Otros calificadores::Otros calificadores::/uso terapéutico ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias hematológicas ENFERMEDADES::neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma de células B Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia Impact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disorders